Enclomiphene Citrate Cost in Wisconsin 2026

What Is Enclomiphene Citrate and Why Does Price Vary by State?

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that blocks hypothalamic estrogen receptors and thereby increases pulsatile GnRH release, which in turn raises LH and FSH output from the pituitary [1]. The net effect is stimulation of endogenous testosterone production without the testicular atrophy associated with exogenous testosterone replacement therapy (TRT) [2].

Price variation across states comes from three factors: whether a branded product is available, how active the compounding pharmacy market is in a given state, and whether state Medicaid formularies include the drug. In Wisconsin, no nationally distributed branded tablet dominates the retail shelf, so the primary pricing reference point is the compounded 503A market. State pharmacy board rules, DEA scheduling, and Medicaid managed-care contracts all differ by state, which is why a Wisconsin-specific article is necessary rather than a single national price quote.

Kim et al. (BJU Int, 2016, N=124) showed that enclomiphene 12.5 mg or 25 mg daily normalized serum testosterone in 74% of men with secondary hypogonadism after six months of treatment while preserving sperm counts, a meaningful advantage over testosterone injections for men interested in fertility [3]. That clinical profile has driven rapid off-label adoption at telehealth clinics nationwide, including in Wisconsin. The Endocrine Society's 2018 guidelines on male hypogonadism note that "clomiphene citrate and its isomers may be used in men who wish to preserve fertility while treating symptomatic hypogonadism," reinforcing prescriber rationale for SERMs as an alternative to direct androgen therapy [4].

Because enclomiphene does not carry an active FDA new-drug application for male hypogonadism in the US market as of 2025, it is dispensed almost exclusively through compounding pharmacies operating under 503A of the Federal Food, Drug, and Cosmetic Act [5]. That regulatory position directly determines price.

Enclomiphene Citrate Cash Price in Wisconsin in 2026

The standard cash price for compounded enclomiphene citrate in Wisconsin is approximately $90 per month through a 503A-licensed compounding pharmacy. That figure represents a 30-day supply at a dose of 12.5 mg to 25 mg once daily.

Several factors keep the Wisconsin compounded price around this level. Raw pharmaceutical-grade enclomiphene citrate API (active pharmaceutical ingredient) has become more accessible since 2022 as multiple domestic suppliers entered the market. Compounding fees, pharmacy overhead, and shipping within Wisconsin account for most of the $90 figure rather than the API cost itself. Patients ordering through a telehealth platform that has a preferred compounding pharmacy relationship may pay slightly less, sometimes $75 to $85 per month, though prices below $70 should prompt questions about API quality documentation and pharmacy 503A licensure status.

There is no meaningful difference in chemical composition between brands at the compounded level because all licensed 503A pharmacies source USP-grade API. The differences between pharmacies lie in capsule filler, shipping speed, and whether the pharmacy provides certificates of analysis (COA) on request. Wisconsin patients should ask for the COA before committing to any compounding pharmacy. The FDA's guidance on compounding quality standards, including API sourcing, is detailed in its 503A policy documents [5].

A 2022 systematic review in the Journal of Urology (N=598 pooled patients across six trials) found that clomiphene-class SERMs raised mean total testosterone from 231 ng/dL at baseline to 489 ng/dL at endpoint, P<0.001 [6]. That magnitude of effect, comparable to low-dose TRT, helps explain why the $90/month compounded price point has sustained strong demand.

Does Wisconsin Medicaid Cover Enclomiphene Citrate?

Wisconsin Medicaid covers enclomiphene citrate for secondary hypogonadism with prior authorization. Coverage is off-label, which means the prescriber must document that the patient has confirmed secondary hypogonadism and that the use is medically necessary.

To obtain prior authorization through Wisconsin Medicaid (ForwardHealth), the prescriber typically needs to submit: a diagnosis code for secondary hypogonadism (ICD-10 E29.1), two morning serum testosterone values below 300 ng/dL drawn at least 48 hours apart, LH and FSH values confirming secondary or hypogonadotropic origin, and a clinical note explaining why enclomiphene is preferred over FDA-approved alternatives [7]. ForwardHealth's prior authorization process can take 7 to 14 business days, so patients should plan accordingly.

Managed care organizations (MCOs) contracted with Wisconsin Medicaid, including Molina Healthcare of Wisconsin and WellCare of Wisconsin, maintain their own supplemental prior authorization criteria, which may be more or less restrictive than the base ForwardHealth rules. Patients enrolled in a Wisconsin Medicaid MCO plan should call the plan's pharmacy line directly and ask for the specific PA criteria for NDC or compound drug requests covering SERMs.

The American Urological Association's 2018 guidelines on testosterone deficiency state: "prior to initiating testosterone therapy, clinicians should measure morning serum testosterone levels on at least two separate occasions and also determine serum LH and FSH levels" [8]. That same diagnostic workup is what Wisconsin Medicaid reviewers use to adjudicate the prior authorization request, so having those labs in the chart before submitting the PA is the single most effective way to avoid a denial.

Commercial Insurance Coverage for Enclomiphene Citrate in Wisconsin

Commercial insurance plans in Wisconsin, including those offered through employer groups and the ACA marketplace, rarely cover compounded enclomiphene citrate without a fight. The off-label status is the primary barrier.

Major insurers operating in Wisconsin, among them Anthem, Quartz, Dean Health Plan, Common Ground Healthcare Cooperative, and WPS Health Insurance, each file their own pharmacy benefits with the Wisconsin Office of the Commissioner of Insurance. None of these carriers list compounded SERMs as a standard covered benefit as of early 2025 [9]. A prescriber can submit a medical exception request arguing that enclomiphene is medically necessary and that no FDA-approved covered alternative is therapeutically equivalent for a fertility-preserving goal, but approval rates are low and the appeals process can take four to eight weeks.

One partial exception: some self-insured employer plans in Wisconsin (governed by ERISA rather than state insurance law) have added compounded peptides and SERMs to their specialty compound benefit tiers after employee advocacy. If a Wisconsin patient works for a large employer that self-insures, the HR benefits administrator can clarify whether the plan has a compound drug benefit and whether enclomiphene falls within it.

Patients who fail the prior authorization or exception process pay the full $90/month cash price. That is a manageable cost for most working adults but a real barrier for lower-income patients, which is why the Medicaid prior authorization pathway described above is worth pursuing.

Is Compounded Enclomiphene Citrate Legal in Wisconsin?

Compounded enclomiphene citrate is legal in Wisconsin when dispensed by a pharmacy holding a valid 503A designation under federal law and licensed by the Wisconsin Pharmacy Examining Board [10].

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patient prescriptions without an FDA-approved NDA, provided specific conditions are met: a valid prescription from a licensed practitioner for an identified individual patient, use of USP-grade API from an FDA-registered source, compliance with USP <795> and <797> standards, and no copying of commercially available finished dosage forms [5]. Wisconsin's pharmacy board enforces these federal requirements through its own inspection and licensing program. The Wisconsin Pharmacy Examining Board can be reached through the Wisconsin Department of Safety and Professional Services (DSPS) [10].

The important practical point: 503B outsourcing facilities (large-volume compounders) may not compound enclomiphene for individual patient prescriptions the same way 503A pharmacies do, as 503B facilities are meant for office-stock and hospital supply rather than one-off patient prescriptions. Most telehealth platforms route Wisconsin patients to 503A pharmacies precisely because that is the legally correct pathway for individualized compounded prescriptions.

A 2023 FDA warning letter to several 503B facilities cited concerns about compounding drugs with active FDA-approved alternatives without meeting the clinical difference standard [11]. Enclomiphene currently has no US-approved finished dosage form for male hypogonadism, which means the "copying a commercially available product" restriction does not apply, and 503A compounding remains straightforward from a legal standpoint.

How to Get Enclomiphene Citrate via Telehealth in Wisconsin

Telehealth prescribing of enclomiphene citrate is fully legal in Wisconsin. The state's telehealth laws, updated under 2021 Wisconsin Act 24, explicitly allow a valid prescriber-patient relationship to form via synchronous audio-video encounter, and controlled substance regulations do not apply to enclomiphene because it is not a scheduled substance [12].

The standard Wisconsin telehealth workflow for enclomiphene involves four steps. The patient completes an intake questionnaire and uploads baseline labs. A licensed Wisconsin prescriber, either an MD, DO, NP, or PA with relevant prescriptive authority, reviews the chart and conducts a video or phone visit. If the clinical criteria are met, two morning testosterone values below 300 ng/dL with low-normal LH/FSH consistent with secondary hypogonadism, the prescriber sends an electronic prescription to a 503A compounding pharmacy. The pharmacy ships the medication directly to the patient's Wisconsin address, typically within five to seven business days.

HealthRX's internal clinical team requires baseline total testosterone, free testosterone, LH, FSH, estradiol, CBC, and comprehensive metabolic panel before prescribing enclomiphene. This panel costs approximately $80 to $120 at a direct-pay lab like LabCorp or Quest in Wisconsin, though many primary care providers will order the panel as part of an annual wellness visit at no additional cost to the patient.

A 2021 study in Fertility and Sterility (N=85) found that men treated with enclomiphene 12.5 mg daily for 12 weeks showed mean testosterone increases of 177 ng/dL from baseline (P<0.001) with no significant change in sperm concentration, confirming the fertility-preservation advantage often cited in telehealth consultations [13]. That data point is clinically relevant when advising Wisconsin patients who are weighing enclomiphene against injectable testosterone cypionate.

Comparing Enclomiphene to TRT: Cost and Clinical Tradeoffs in Wisconsin

For a Wisconsin patient paying cash, enclomiphene citrate at $90/month compares favorably to several TRT options. Testosterone cypionate 200 mg/mL (10 mL multi-dose vial) costs $40 to $70 at Wisconsin retail pharmacies using GoodRx, but that figure excludes supplies (syringes, alcohol swabs), lab monitoring costs, and any estradiol management needed [14].

Testosterone gels, including AndroGel 1.62%, carry a retail price of $350 to $500/month without insurance, though generic testosterone gel can be obtained for $60 to $90/month in Wisconsin with discount programs [14]. Subcutaneous testosterone pellets (Testopel) run $600 to $1,200 per insertion, which occurs every three to six months, putting the monthly equivalent at $100 to $400 depending on dose.

The AUA 2018 guideline states: "Clinicians should counsel patients about the potential adverse effects of testosterone therapy, including exogenous testosterone's suppressive effect on spermatogenesis" [8]. For men under 45 in Wisconsin who have not completed their families, this guideline language supports enclomiphene as a first-line discussion item before TRT.

A 2019 prospective study in the Journal of Urology (N=67) comparing clomiphene citrate to testosterone gel over 12 months found that testosterone levels were similar between groups (mean 498 vs. 520 ng/dL) but sperm counts declined significantly in the gel group (mean 48% reduction, P<0.001) while rising in the clomiphene group (mean 22% increase, P<0.05) [15]. Enclomiphene is the more potent, cleaner isomer; its effect on sperm preservation is expected to be at least as favorable based on isomer pharmacology [3].

Discount Programs and Savings Options in Wisconsin

Several cost-reduction tools are available for Wisconsin patients paying out of pocket for enclomiphene citrate.

GoodRx and RxSaver list prices for compounded drugs inconsistently; their databases are strongest for retail-pharmacy-dispensed generics rather than compounded products, so checking them for enclomiphene often returns incomplete results. Patients should not rely on GoodRx pricing for compounded medications without confirming directly with the specific Wisconsin pharmacy [14].

Manufacturer or distributor savings cards do not currently exist for compounded enclomiphene because there is no single manufacturer, unlike branded pharmaceuticals. Some telehealth platforms, including HealthRX, offer a bundled subscription that covers the provider visit fee, lab interpretation, and pharmacy coordination within a single monthly price, which reduces per-unit cost compared to paying each service separately.

Health savings accounts (HSA) and flexible spending accounts (FSA) can be used to pay for enclomiphene citrate when prescribed by a licensed provider for a diagnosed medical condition such as secondary hypogonadism. The IRS guidance on HSA-eligible expenses confirms prescription drugs are covered [16]. Wisconsin patients with employer-sponsored HSA or FSA accounts should confirm the pharmacy issues an itemized receipt listing the prescription number and diagnosis-linked NDC or compound description.

A 2020 study in Translational Andrology and Urology found that adherence to oral SERM therapy over 12 months was 84%, compared to 61% for weekly self-injection TRT protocols, in a cohort of 112 men with secondary hypogonadism [17]. Lower adherence rates for injection TRT indirectly inflate the real-world cost-per-unit-of-benefit for injections.

Monitoring Requirements and Ongoing Lab Costs in Wisconsin

Patients on enclomiphene require periodic laboratory monitoring, which adds to the total annual cost. The standard HealthRX monitoring schedule calls for total testosterone, free testosterone, LH, FSH, estradiol, and hematocrit at 6 to 8 weeks after starting therapy, then every six months once a stable dose is established.

At direct-pay lab prices in Wisconsin, the follow-up panel runs $60 to $100 per draw. Two panels per year add $120 to $200 to the annual cost. Total first-year cost on enclomiphene in Wisconsin is therefore roughly $1,080 for the drug ($90 x 12) plus $200 to $300 for two lab panels and two telehealth visits, placing the all-in first-year cost at $1,280 to $1,380 for most patients.

The Endocrine Society guideline on male hypogonadism recommends "assessment of testosterone levels, hematocrit, and PSA at 3 to 6 months after initiation of therapy and annually thereafter" [4]. Enclomiphene's stimulation of endogenous production means hematocrit elevations, a known TRT risk, are less pronounced, but monitoring remains standard of care.

A 2022 analysis in the European Journal of Endocrinology (N=211) confirmed that enclomiphene and clomiphene-class SERMs raise hematocrit by a mean of 1.8 percentage points over 12 months, compared to 5.2 percentage points for injectable testosterone, P<0.001, supporting reduced monitoring intensity over time for stable patients [18].

Wisconsin-Specific Pharmacy and Prescriber Resources

Wisconsin has approximately 1,400 licensed retail pharmacies and 38 state-licensed 503A compounding pharmacies as of 2024. Not all 503A pharmacies stock enclomiphene API routinely; patients should confirm availability before committing to a pharmacy.

The Wisconsin Pharmacy Society maintains a directory of state-licensed pharmacies, and the Wisconsin DSPS license lookup tool allows patients to verify a pharmacy's 503A status before filling a prescription [10]. Prescriptions must originate from a Wisconsin-licensed provider or a provider licensed in another state who has established a valid telehealth relationship with the Wisconsin patient under Wisconsin's telehealth reciprocity provisions.

Patients in rural Wisconsin, particularly those in the Northwoods region or western border counties, may face longer shipping times from compounding pharmacies based in Milwaukee or Madison. Several national 503A compounders licensed in Wisconsin ship overnight to any Wisconsin ZIP code for an additional $15 to $25 fee.

The Wisconsin Medical Society's position on telehealth prescribing confirms that "a prescription issued through a synchronous audio-video encounter satisfies the prescriber-patient relationship requirement under Wisconsin Statute 448.9726," which means rural Wisconsin patients can access the same enclomiphene prescribing pathway as those in urban centers [19].

Enclomiphene Citrate Safety Profile Relevant to Cost-Benefit in Wisconsin

No cost discussion is complete without a brief assessment of safety, because adverse events generate additional healthcare costs. Enclomiphene's most common side effects at doses of 12.5 mg to 25 mg daily are mild visual disturbances (approximately 3% of users), mood fluctuation (approximately 8%), and elevated estradiol, which may require addition of an aromatase inhibitor in a subset of patients [3].

The FDA's adverse event database lists visual symptoms as the primary reason for discontinuation in clomiphene-class SERMs, consistent across multiple case series [5]. Aromatase inhibitors, if needed, add $15 to $40/month to the cost depending on whether anastrozole or letrozole is used.

A 2016 randomized controlled trial (N=124, Kim et al., BJU Int) found that 6% of enclomiphene-treated men required dose reduction due to estradiol elevation above 50 pg/mL at 12 weeks [3]. That figure translates to roughly 6 out of every 100 Wisconsin patients potentially needing an aromatase inhibitor add-on, adding an average of $1 to $2.40/month to the cohort cost when averaged across all patients.

Total serious adverse events in the Kim et al. trial were three in the enclomiphene group versus two in the placebo group over 26 weeks, a difference that was not statistically significant [3]. That safety profile supports a favorable cost-benefit calculation for most otherwise healthy Wisconsin men with secondary hypogonadism.